Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "ELUTIA INC." but the filing is for Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 21, 2023
Event Date: April 20, 2023
Context: The Company entered into a Material Definitive Agreement with LeMaitre Vascular, Inc. to establish an exclusive distribution arrangement for specific product lines in the United States.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreement Details
On April 20, 2023, Aziyo Biologics, Inc. entered into a Distribution Agreement with LeMaitre Vascular, Inc. Key terms include:
- Scope: LeMaitre appointed as the exclusive distributor for ProxiCor® PC, ProxiCor® CTR, Tyke®, and VasCure® product lines in the United States.
- Term: Three-year initial period, subject to extension by mutual agreement.
- Purchase Obligations: Includes an initial purchase and subsequent purchases subject to minimum volume requirements beginning October 1, 2023.
- Pricing: Product prices are subject to annual adjustment by Aziyo with prior written notice.
- Acquisition Option: LeMaitre holds an exclusive option, exercisable during the final two years of the term, to acquire all rights to the Products and related assets. The purchase price would be based on a multiple of trailing twelve-month worldwide sales, subject to a specified minimum.
- Termination: Either party may terminate for bankruptcy/insolvency or material breach. LeMaitre may terminate after the first anniversary; Aziyo may terminate if minimum volume requirements are not met.
Outlook, Risks, and Contingencies
Management Commentary: The Company issued a press release announcing the agreement. The full text of the agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Specific risks identified include:
- Ability to successfully execute the distribution arrangement with LeMaitre.
- Inability to generate sufficient revenue to achieve or sustain profitability.
- Adverse economic conditions and credit market instability.
- Going concern status.
- Impact of the recall of a single lot of the FiberCel product and its discontinuation by a distribution partner.
- Dependence on commercial partners and physician acceptance of products.
- Regulatory approval and intellectual property rights.
Investor Verification Checklist
- Verify the specific minimum purchase volume requirements effective October 1, 2023, once the full agreement is filed in the 10-Q.
- Confirm the "specified minimum" purchase price for the potential acquisition option held by LeMaitre.
- Review the Company's most recent 10-K and 10-Q filings for updated financial status and details on the FiberCel product recall impact.
- Monitor future press releases for the execution of the initial purchase under the new agreement.